United Therapeutics (UTHR) Tops Q1 EPS by 19c, Miss on Revenues
Tweet
Share
E-mailGet Alerts UTHR Hot Sheet
Price: $487.61 -0.54%
EPS Growth %: -10.1%
Financial Fact:
Research and development: 45.9M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: -10.1%
Financial Fact:
Research and development: 45.9M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
United Therapeutics (NASDAQ: UTHR) reported Q1 EPS of $3.76, $0.19 better than the analyst estimate of $3.57. Revenue for the quarter came in at $389.2 million versus the consensus estimate of $401.94 million.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- Ambarella (AMBA) Tops Q2 EPS by 1c; offers guidance
- Ciena (CIEN) Tops Q3 EPS by 39c, Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
